In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus

被引：36

作者：

Boos, M

Mayer, S

Fischer, A

Köhrer, K

Scheuring, S

Heisig, P

Verhoef, J

Fluit, AC

Schmitz, FJ

机构：

[1] Univ Dusseldorf, Inst Med Microbiol & Virol, D-40225 Dusseldorf, Germany

[2] Univ Bonn, Inst Pharmaceut Microbiol, D-5300 Bonn, Germany

[3] Univ Med Ctr Utrecht, Eijkman Winkler Inst Med Microbiol, Utrecht, Netherlands

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2001年 / 45卷 / 03期

关键词：

D O I：

10.1128/AAC.45.3.938-942.2001

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus isolates were exposed to subinhibitory MICs of ciprofloxacin, sparfloxacin, gatifloxacin, moxifloxacin, clinafloxacin, and gemifloxacin during a 10-day period. Subculturing led to resistance development, regardless of the initial potencies of the quinolones. None of the quinolones was associated with a significantly slower rate of resistance development.

引用

页码：938 / 942

页数：5

共 44 条

[1] A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus:: Evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux
Beyer, R
Pestova, E
Millichap, JJ
Stosor, V
Noskin, GA
Peterson, LR
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) : 798 - 801
[2] Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms
Blondeau, JM
Laskowski, R
Bjarnason, J
Stewart, C
[J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 14 (01) : 45 - 50
[3] Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae
Brenwald, NP
Gill, MJ
Wise, R
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) : 2032 - 2035
[4] Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
Chen, DK
McGeer, A
de Azavedo, JC
Low, DE
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) : 233 - 239
[5] In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae
Davies, TA
Pankuch, GA
Dewasse, BE
Jacobs, MR
Appelbaum, PC
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) : 1177 - 1182
[6] Antipneumococcal activities of gemifloxacin compared to those of nine other agents
Davies, TA
Kelly, LM
Pankuch, GA
Credito, KL
Jacobs, MR
Appelbaum, PC
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) : 304 - 310
[7] In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae
Davies, TA
Dewasse, BE
Appelbaum, PC
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) : 414 - 417
[8] DNA gyrase, topoisomerase IV, and the 4-quinolones
Drlica, K
Zhao, XL
[J]. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 1997, 61 (03) : 377 - +
[9] Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium
El Amin, N
Jalal, S
Wretlind, B
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) : 947 - 949
[10] Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci
Ferrándiz, MJ
Oteo, J
Aracil, B
Gómez-Garcés, JL
de la Campa, AG
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) : 2520 - 2523

← 1 2 3 4 5 →